{"id":"alfacalcidol","rwe":[],"tags":[{"label":"alfacalcidol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent noradrenaline transporter","category":"target"},{"label":"SLC6A2","category":"gene"},{"label":"VDR","category":"gene"},{"label":"A11CC03","category":"atc"},{"label":"Active","category":"status"},{"label":"Hyperparathyroidism","category":"indication"},{"label":"Hypoparathyroidism","category":"indication"},{"label":"Neonatal hypocalcemia","category":"indication"},{"label":"Renal osteodystrophy","category":"indication"},{"label":"Bone Density Conservation Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":475.381,"date":"","count":209,"signal":"Muscle spasticity","source":"DrugCentral FAERS","actionTaken":"Reported 209 times (LLR=475)"},{"llr":402.929,"date":"","count":212,"signal":"Ear pain","source":"DrugCentral FAERS","actionTaken":"Reported 212 times (LLR=403)"},{"llr":362.436,"date":"","count":223,"signal":"Respiratory disorder","source":"DrugCentral FAERS","actionTaken":"Reported 223 times (LLR=362)"},{"llr":357.594,"date":"","count":216,"signal":"Body temperature increased","source":"DrugCentral FAERS","actionTaken":"Reported 216 times (LLR=358)"},{"llr":333.844,"date":"","count":221,"signal":"Night sweats","source":"DrugCentral FAERS","actionTaken":"Reported 221 times (LLR=334)"},{"llr":276.246,"date":"","count":183,"signal":"Hypocalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 183 times (LLR=276)"},{"llr":229.714,"date":"","count":57,"signal":"Shunt stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=230)"},{"llr":200.969,"date":"","count":249,"signal":"Lower respiratory tract infection","source":"DrugCentral FAERS","actionTaken":"Reported 249 times (LLR=201)"},{"llr":164.017,"date":"","count":122,"signal":"Hypercalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 122 times (LLR=164)"},{"llr":147.628,"date":"","count":251,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 251 times (LLR=148)"},{"llr":144.37,"date":"","count":41,"signal":"Shunt occlusion","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=144)"},{"llr":141.842,"date":"","count":219,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 219 times (LLR=142)"},{"llr":141.492,"date":"","count":147,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 147 times (LLR=141)"},{"llr":132.869,"date":"","count":140,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 140 times (LLR=133)"},{"llr":129.966,"date":"","count":113,"signal":"Osteonecrosis of jaw","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=130)"}],"commonSideEffects":[{"effect":"Muscle spasticity","drugRate":"LLR 475","severity":"common"},{"effect":"Ear pain","drugRate":"LLR 403","severity":"common"},{"effect":"Respiratory disorder","drugRate":"LLR 362","severity":"common"},{"effect":"Body temperature increased","drugRate":"LLR 358","severity":"common"},{"effect":"Night sweats","drugRate":"LLR 334","severity":"common"},{"effect":"Hypocalcaemia","drugRate":"LLR 276","severity":"common"},{"effect":"Shunt stenosis","drugRate":"LLR 230","severity":"common"},{"effect":"Lower respiratory tract infection","drugRate":"LLR 201","severity":"common"},{"effect":"Hypercalcaemia","drugRate":"LLR 164","severity":"common"},{"effect":"Urticaria","drugRate":"LLR 148","severity":"common"},{"effect":"Shunt occlusion","drugRate":"LLR 144","severity":"common"},{"effect":"Renal impairment","drugRate":"LLR 142","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 133","severity":"common"},{"effect":"Osteonecrosis of jaw","drugRate":"LLR 130","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T13:12:24.516611","allNames":"alfarol","offLabel":[],"synonyms":["alfacalcidol","1alpha-Hydroxycholecalciferol","alfarol","alphacalcidol","einsalpha","alpha-calcidol","1-hydroxycholecalciferol"],"timeline":[{"date":"1978-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"brandName":"Alfarol","ecosystem":[{"indication":"Hyperparathyroidism","otherDrugs":[],"globalPrevalence":null},{"indication":"Hypoparathyroidism","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"parathyroid hormone","slug":"parathyroid-hormone","company":"Nps Pharms Inc"}],"globalPrevalence":null},{"indication":"Neonatal hypocalcemia","otherDrugs":[],"globalPrevalence":null},{"indication":"Renal osteodystrophy","otherDrugs":[{"name":"calcifediol","slug":"calcifediol","company":""},{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Sodium-dependent noradrenaline transporter","targets":[{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"}],"modality":"Small Molecule","drugClass":"alfacalcidol","explanation":"Think of vitamin D like a key that unlocks the body's ability to absorb calcium from food. When vitamin D is activated, it helps the body use calcium to build strong bones and teeth, and also helps the body absorb calcium from the food we eat.","oneSentence":"Alfarol works by activating vitamin D receptors in the body, which helps regulate calcium levels.","technicalDetail":"Alfacalcidol is a secosteroid that is converted to its active form, 1,25-dihydroxyvitamin D3, in the liver and kidneys, which then binds to vitamin D receptors to regulate calcium homeostasis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/130","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALFACALCIDOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALFACALCIDOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:36:37.893612","biosimilars":[],"competitors":[{"drugName":"ergocalciferol","drugSlug":"ergocalciferol","fdaApproval":"1941-01-11","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-class"},{"drugName":"calcifediol","drugSlug":"calcifediol","fdaApproval":"1980-08-05","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"alfacalcidol","indications":{"approved":[{"name":"Hyperparathyroidism","source":"DrugCentral","snomedId":66999008,"regulator":"FDA"},{"name":"Hypoparathyroidism","source":"DrugCentral","snomedId":36976004,"regulator":"FDA"},{"name":"Neonatal hypocalcemia","source":"DrugCentral","snomedId":268846006,"regulator":"FDA"},{"name":"Renal osteodystrophy","source":"DrugCentral","snomedId":16726004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(771)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ergocalciferol","brandName":"ergocalciferol","genericName":"ergocalciferol","approvalYear":"1941","relationship":"same-class"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-class"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-class"},{"drugId":"calcifediol","brandName":"calcifediol","genericName":"calcifediol","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07455656","phase":"NA","title":"Assessment of the Locally Administrated Vitamin D3 and Corticision Efficacy on Orthodontic Canine Retraction","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-08-01","conditions":["Malocclusions","Canine Retraction"],"enrollment":16,"completionDate":"2027-08-01"},{"nctId":"NCT07381998","phase":"NA","title":"Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life","status":"ENROLLING_BY_INVITATION","sponsor":"Aarhus University Hospital","startDate":"2026-01-01","conditions":["Hypoparathyroidism Post-surgical","Quality of Life"],"enrollment":150,"completionDate":"2028-12"},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":["Pentoxifylline","Inflammatory Markers","Non-Diabetic","Chronic Kidney Disease"],"enrollment":42,"completionDate":"2023-08-31"},{"nctId":"NCT05680818","phase":"PHASE3","title":"Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calcilytix Therapeutics, Inc., a BridgeBio company","startDate":"2023-01-06","conditions":["Autosomal Dominant Hypocalcemia (ADH)"],"enrollment":67,"completionDate":"2029-08"},{"nctId":"NCT03210688","phase":"PHASE4","title":"Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2018-05-01","conditions":["Minimal Change Disease","Nephrotic Syndrome"],"enrollment":71,"completionDate":"2025-01-21"},{"nctId":"NCT03582917","phase":"PHASE2","title":"The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis","status":"RECRUITING","sponsor":"University of Ioannina","startDate":"2018-09-20","conditions":["Scoliosis; Adolescence"],"enrollment":80,"completionDate":"2025-12-20"},{"nctId":"NCT06571344","phase":"","title":"Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2022-11-01","conditions":["Vitamin D Deficiency Due to Chronic Kidney Disease"],"enrollment":160,"completionDate":"2026-12-31"},{"nctId":"NCT06385093","phase":"PHASE4","title":"A Study on the Prevention and Treatment of GIOP With Eldecalcitol","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2024-06","conditions":["Rheumatoid Arthritis","Osteoporosis","Osteopenia"],"enrollment":314,"completionDate":"2026-03"},{"nctId":"NCT06272227","phase":"PHASE4","title":"Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2024-02-13","conditions":["Sarcopenia"],"enrollment":340,"completionDate":"2025-09-01"},{"nctId":"NCT04967469","phase":"NA","title":"Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-09-01","conditions":["End Stage Renal Disease"],"enrollment":60,"completionDate":"2023-12-30"},{"nctId":"NCT06016400","phase":"PHASE2,PHASE3","title":"Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-06-14","conditions":["Oral Squamous Cell Carcinoma","Oral Mucositis"],"enrollment":412,"completionDate":"2024-04-30"},{"nctId":"NCT04750460","phase":"PHASE3","title":"Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).","status":"COMPLETED","sponsor":"Saint Petersburg State University, Russia","startDate":"2021-03-01","conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease-Mineral and Bone Disorder","Dialysis","Hypocalcemia","Hypoparathyroidism"],"enrollment":20,"completionDate":"2022-02-16"},{"nctId":"NCT05505253","phase":"PHASE3","title":"Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2020-11-01","conditions":["Pelvic Organ Prolapse"],"enrollment":48,"completionDate":"2021-12-31"},{"nctId":"NCT02306187","phase":"PHASE1","title":"The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2014-12","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT03183557","phase":"PHASE2","title":"Efficacy of Zoledronic Acid in Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2017-10-12","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2025-06-08"},{"nctId":"NCT02824718","phase":"PHASE2","title":"Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-06","conditions":["Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment"],"enrollment":16,"completionDate":"2020-05-28"},{"nctId":"NCT04166253","phase":"PHASE2","title":"Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-09-01","conditions":["Breast Cancer"],"enrollment":100,"completionDate":"2020-05-01"},{"nctId":"NCT03182699","phase":"PHASE4","title":"Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rainer Oberbauer","startDate":"2017-10-01","conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease Requiring Chronic Dialysis","Left Ventricular Hypertrophy"],"enrollment":62,"completionDate":"2019-12-20"},{"nctId":"NCT04405960","phase":"PHASE3","title":"Role of Alphacalcidol Supplement to Reduce Pain and COMP in Geriatric Knee Osteoarthritis Patients","status":"COMPLETED","sponsor":"Syarif Hidayatullah State Islamic University Jakarta","startDate":"2017-07-01","conditions":["Osteoarthritis, Knee","Aged"],"enrollment":146,"completionDate":"2017-12-31"},{"nctId":"NCT02993302","phase":"PHASE2","title":"Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients","status":"COMPLETED","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2014-07","conditions":["Graves Disease"],"enrollment":25,"completionDate":"2015-03"},{"nctId":"NCT04146259","phase":"","title":"Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism","status":"COMPLETED","sponsor":"University of Athens","startDate":"2017-01-01","conditions":["Hypoparathyroidism Postprocedural"],"enrollment":109,"completionDate":"2019-08-01"},{"nctId":"NCT03147677","phase":"PHASE4","title":"Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2016-07-28","conditions":["Type 2 Diabetic Nephropathy"],"enrollment":60,"completionDate":"2018-12-30"},{"nctId":"NCT04085770","phase":"PHASE4","title":"Short Term Effect of Vitamin D Supplementation on the Clinical Outcomes in Patients Undergoing Valve Replacement Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-04-01","conditions":["Cardiac Valve Replacement Complication"],"enrollment":86,"completionDate":"2019-09-03"},{"nctId":"NCT03777033","phase":"NA","title":"Systematic Administration of Calcium and Vitamin D After Thyroidectomy","status":"UNKNOWN","sponsor":"Hellenic Red Cross Hospital","startDate":"2015-03-01","conditions":["Thyroid Diseases"],"enrollment":160,"completionDate":"2020-08-04"},{"nctId":"NCT01181531","phase":"PHASE4","title":"Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-10-01","conditions":["Hyperparathyroidism, Secondary"],"enrollment":312,"completionDate":"2012-08-14"},{"nctId":"NCT01656512","phase":"PHASE3","title":"Zometa Study in Pediatric Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Cancer Hospital Egypt 57357","startDate":"2011-10","conditions":["Osteoporosis"],"enrollment":95,"completionDate":"2015-08"},{"nctId":"NCT03496246","phase":"NA","title":"Vitamin D Status in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-04","conditions":["Vitamin D Deficiency","Inflammatory Bowel Diseases"],"enrollment":50,"completionDate":"2019-06"},{"nctId":"NCT03292744","phase":"PHASE4","title":"Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2017-01-10","conditions":["Frail Elderly Syndrome","Elderly Infection"],"enrollment":110,"completionDate":"2017-12-15"},{"nctId":"NCT02895061","phase":"NA","title":"Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.","status":"COMPLETED","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2015-01","conditions":["Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis"],"enrollment":502,"completionDate":"2016-01"},{"nctId":"NCT01057186","phase":"","title":"Hypophosphatemic Rickets in Norway","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2009-12","conditions":["Hypophosphatemia, Familial","Rickets","Hyperphosphatemia"],"enrollment":80,"completionDate":""},{"nctId":"NCT01774812","phase":"PHASE2","title":"Vitamin D and Cardiac Autonomic Tone in Hemodialysis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2013-01","conditions":["Cardiovascular Disease","Sudden Cardiac Death"],"enrollment":56,"completionDate":"2015-03"},{"nctId":"NCT02747381","phase":"PHASE4","title":"The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-08","conditions":["Asthma"],"enrollment":82,"completionDate":"2016-04"},{"nctId":"NCT00828347","phase":"NA","title":"Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2008-01","conditions":["Secondary Hyperparathyroidism"],"enrollment":35,"completionDate":"2009-07"},{"nctId":"NCT02327091","phase":"PHASE3","title":"The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2012-04","conditions":["Muscle Weakness"],"enrollment":122,"completionDate":"2012-12"},{"nctId":"NCT01974167","phase":"NA","title":"Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol","status":"UNKNOWN","sponsor":"e-GLORIA trial Protocol Review Committee","startDate":"2013-12","conditions":["Osteoporosis"],"enrollment":400,"completionDate":""},{"nctId":"NCT00165698","phase":"PHASE3","title":"Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2005-05","conditions":["Postmenopausal Osteoporosis"],"enrollment":240,"completionDate":"2007-07"},{"nctId":"NCT00144456","phase":"PHASE3","title":"A New Active Vitamin D, ED-71 for Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2004-09","conditions":["Osteoporosis"],"enrollment":1056,"completionDate":"2008-10"},{"nctId":"NCT01896609","phase":"PHASE4","title":"Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2013-06","conditions":["Chronic Hepatitis c"],"enrollment":300,"completionDate":"2015-06"},{"nctId":"NCT01765010","phase":"PHASE4","title":"The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2013-01","conditions":["Osteoporosis"],"enrollment":88,"completionDate":"2013-03"},{"nctId":"NCT01752244","phase":"NA","title":"Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2012-01","conditions":["Obesity"],"enrollment":94,"completionDate":"2013-01"},{"nctId":"NCT01231438","phase":"PHASE2","title":"Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2010-10","conditions":["Kidney Failure"],"enrollment":21,"completionDate":"2011-03"},{"nctId":"NCT00977080","phase":"PHASE4","title":"Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-11","conditions":["Chronic Kidney Disease","Secondary Hyperparathyroidism","Hemodialysis"],"enrollment":272,"completionDate":"2011-05"},{"nctId":"NCT00668330","phase":"PHASE4","title":"Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-04","conditions":["Systemic Lupus Erythematosus"],"enrollment":40,"completionDate":"2009-05"},{"nctId":"NCT01084538","phase":"","title":"Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-09","conditions":["Parathyroid Hormone"],"enrollment":181,"completionDate":"2010-06"},{"nctId":"NCT00483275","phase":"PHASE4","title":"Fall Prevention by Alfacalcidol and Training","status":"WITHDRAWN","sponsor":"Ruhr University of Bochum","startDate":"2007-06","conditions":["Accidental Falls","Chronic Renal Insufficiency","Aged"],"enrollment":484,"completionDate":"2009-09"},{"nctId":"NCT01364688","phase":"PHASE2","title":"Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Ramathibodi Hospital","startDate":"2011-05","conditions":["Vascular Calcification"],"enrollment":80,"completionDate":"2012-12"},{"nctId":"NCT00469599","phase":"NA","title":"Treatment of Secondary Hyperparathyroidism in the Uremic Patient","status":"TERMINATED","sponsor":"Zealand University Hospital","startDate":"2007-07","conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease","Vitamin D Deficiency"],"enrollment":86,"completionDate":"2010-10"},{"nctId":"NCT01115543","phase":"PHASE4","title":"Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-08","conditions":["Secondary Hyperparathyroidism","End Stage Renal Disease"],"enrollment":32,"completionDate":"2009-08"},{"nctId":"NCT01020253","phase":"NA","title":"The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)","status":"UNKNOWN","sponsor":"Yokohama City University Medical Center","startDate":"2006-01","conditions":["Bone Density","Arthroplasty, Replacement, Hip"],"enrollment":60,"completionDate":""},{"nctId":"NCT00168909","phase":"PHASE4","title":"Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2003-06","conditions":["Osteoporosis, Postmenopausal","Osteopenia","Falls"],"enrollment":282,"completionDate":"2008-05"},{"nctId":"NCT00630214","phase":"PHASE2","title":"Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2004-05","conditions":["Hypocalcemia"],"enrollment":200,"completionDate":"2006-02"},{"nctId":"NCT00138983","phase":"PHASE3","title":"Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2000-05","conditions":["Rheumatoid Arthritis","Polymyalgia Rheumatica","Giant Cell Arteritis","Polymyositis","Wegener's Granulomatosis"],"enrollment":200,"completionDate":"2003-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003501","UNII":"URQ2517572","CHEBI":"CHEBI:31186","INN_ID":"4489","RXNORM":"12062","UMLSCUI":"C0044410","ChEMBL_ID":"CHEMBL1601669","KEGG_DRUG":"D01518","DRUGBANK_ID":"DB01436","PDB_CHEM_ID":"M9B","PUBCHEM_CID":"5282181","SNOMEDCT_US":"11984007","MESH_SUPPLEMENTAL_RECORD_UI":"C008088"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"48.6 hours","clearance":"0.82 mL/min/kg","bioavailability":"71%"},"publicationCount":771,"therapeuticAreas":["Nephrology"],"atcClassification":{"source":"DrugCentral","atcCode":"A11CC03","allCodes":["A11CC03","M05BB06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41905593","title":"A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy.","journal":"Kidney international"},{"date":"2026 Feb","pmid":"41853424","title":"Delayed Onset Hypoparathyroidism Following Thyroidectomy: Case Report and Review of Literature.","journal":"Cureus"},{"date":"2026","pmid":"41765491","title":"[Relationship between Hypercalcemia and Renal Function with Eldecalcitol].","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan"},{"date":"2026 Feb 24","pmid":"41732805","title":"Autosomal dominant hypocalcemia type 1: Status quo of tailored management and future perspectives.","journal":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"date":"2026 Mar 4","pmid":"41712492","title":"Determinants of extracellular fluid calcium concentration in patients with chronic hypoparathyroidism.","journal":"European journal of endocrinology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alfarol is a medication used to treat osteoporosis. It is administered in a dose of 1.0 µg.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}